Difei Yang
Stock Analyst at Mizuho
(2.18)
# 2,747
Out of 4,876 analysts
33
Total ratings
31.03%
Success rate
11.79%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $3.65 | -45.21% | 4 | Mar 31, 2022 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $18.00 | +1,011.11% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $1.20 | +3,066.67% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $725 | $5.22 | +13,788.89% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $13.86 | +275.18% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $17.11 | +835.13% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $4.70 | +197.87% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $315 → $525 | $25.76 | +1,938.04% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.01 | - | 2 | Aug 8, 2018 | |
| RGNX REGENXBIO | Initiates: Neutral | $28 | $8.39 | +233.73% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $2.14 | +1,208.41% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $3.65
Upside: -45.21%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $18.00
Upside: +1,011.11%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $1.20
Upside: +3,066.67%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $725
Current: $5.22
Upside: +13,788.89%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $13.86
Upside: +275.18%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $17.11
Upside: +835.13%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $4.70
Upside: +197.87%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $315 → $525
Current: $25.76
Upside: +1,938.04%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.01
Upside: -
REGENXBIO
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $8.39
Upside: +233.73%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $2.14
Upside: +1,208.41%